Study guide

5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5)

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5)

Key Takeaways Explain This Topic AI

Each year a program must present at least 15% of its annual analytic caseload at multidisciplinary cancer case conferences, and at least 80% of the cases presented must be prospective.

Prospective cases include newly diagnosed patients before treatment decisions are complete, previously treated patients who need decisions on adjuvant, recurrence or progression treatment, and patients who need supportive or palliative care decisions.

A general cancer case conference must include physician representatives from surgery, pathology, radiology, radiation oncology and medical oncology; programs define required specialties for site-specific conferences.

For each case, the discussion covers clinical and/or pathological stage, treatment planning with evidence-based national guidelines, and, where applicable, genetic testing, clinical research and supportive care options.

The Cancer Conference Coordinator presents an annual report with a full calendar year of data at the first-quarter cancer committee meeting of the following year.

Last updated: September 2026

Why cancer conferences matter

A multidisciplinary cancer case conference , often called a tumor board, brings the specialists who diagnose and treat cancer together to plan care for individual patients. CoC's 2020 standards explain the rationale: outcomes are better when patients are managed by a multidisciplinary team, which improves clinical decisions, outcomes and patient experience. Registrars usually run the logistics and the data. They screen and schedule cases, prepare staging summaries, record attendance and recommendations, and compile the statistics the Cancer Conference Coordinator reports. NCRA's role delineation study lists "coordinate cancer conference activities," "document cancer conference activities," and "facilitate discussion of NCCN guidelines, prognostic indicators, and options for clinical trial participation" as registrar tasks.

Standard 2.5 at a glance

Requirement Detail

Protocol A written conference protocol that addresses multidisciplinary participation, the frequency and format of conferences, the required elements of discussion, the number of cases and the percentage presented prospectively, and methods for correcting areas that fall below the protocol's levels. It must be approved by the cancer committee, like every protocol.

  • Case volume At least 15% of the annual analytic caseload presented each year
  • Prospective share At least 80% of cases presented must be prospective

Repeat presentations The same patient may be presented more than once and counted as prospective each time treatment management issues are discussed

Format A general multidisciplinary conference, with or without site-specific conferences; or only site- or specialty-specific conferences, as long as there is a way to present cases that fit none of them. The program sets the frequency in its protocol.

Attendance Physician attendance at a general conference must include surgery, pathology, radiology, radiation oncology and medical oncology. The program defines the required specialties for site- or specialty-specific conferences. Genetics, clinical research, palliative care, psychosocial, rehabilitation and supportive services representatives are recommended.

Monitoring The Cancer Conference Coordinator monitors and evaluates conference activity and reports to the cancer committee

Documentation The site reviewer attends a conference during the site visit. The protocol, the conference template, the coordinator's report and the minutes are submitted with the Pre-Review Questionnaire. The method of documenting conference activity is left to the cancer committee.

What counts as prospective

CoC's definition is broader than "before any treatment." Prospective cases include, but are not limited to:

Newly diagnosed patients whose treatment has not started, or has started but a decision about additional treatment is needed.

Previously diagnosed patients who have completed initial treatment and need a decision about adjuvant treatment or treatment for recurrence or progression .

Previously diagnosed patients who need a decision about supportive or palliative care .

A retrospective presentation is one with no open management decision. Examples include an educational review of a patient whose treatment ended years ago, or a morbidity and mortality style review after the patient's death. Retrospective presentations count in the total number of cases presented, but not toward the 80% prospective share.

Worked example: counting the numbers

A program's annual analytic caseload is 1,000 cases.

Minimum presentations: 15% of 1,000 = 150 .

Minimum prospective presentations: 80% of the cases presented. If exactly 150 are presented, at least 120 must be prospective.

If the program presents 180 cases and 140 are prospective, then 140/180 = 77.8%, which is below the 80% requirement even though the 15% volume requirement is met. The coordinator's report must include an action plan .

Elements of discussion

The protocol and the coordinator's report must show that each case discussion included, as applicable:

Clinical and/or pathological stage. Registrars often prepare a draft AJCC stage for the presenting physician.

Treatment planning using evidence-based national guidelines , such as the NCCN Guidelines.

Options and eligibility for genetic testing , where applicable.

Options and eligibility for clinical research studies , where applicable.

Options and eligibility for supportive care services , where applicable.

The Cancer Conference Coordinator's annual report

The coordinator presents the report at the first-quarter cancer committee meeting, and it must contain the previous full calendar year of data. It must include:

Conference frequency.

Multidisciplinary physician attendance, measured against the specialties the protocol requires.

The number of cases presented and the percentage that were prospective.

Whether each required element of discussion took place.

An action plan for any area that did not meet the protocol.

An ODS may serve as the Cancer Conference Coordinator (Standard 2.1), which is one of only two coordinator roles an ODS may hold.

The registrar's workflow

Phase Registrar tasks

Before Receive case requests; screen for analytic status and prospective intent; draft a case summary (history, imaging, pathology, biomarkers, draft stage); ask pathology and radiology to review the material; post the agenda

During Record attendance by specialty; document the stage discussed, guideline-based recommendations, genetic and trial eligibility discussion and supportive care referrals, without adding identifiers beyond what the program's documentation policy allows

After Log each presentation (date, conference type, prospective or not, elements discussed); link the discussion to the abstract where the software allows; compile the annual statistics for the coordinator

Conference records may be protected by state peer review statutes, so follow the program's privacy and documentation rules. CoC states that programs are expected to follow local, state and federal requirements on privacy, risk management and peer review.

Exam traps

Standard number. Cancer conferences are Standard 2.5 . Standard 2.2 is the Cancer Liaison Physician.

15% vs. 80%. 15% is the share of the annual analytic caseload that must be presented; 80% is the share of presented cases that must be prospective.

Prospective does not mean "before any treatment." A previously treated patient presented for a decision about treating a recurrence is prospective.

Loading diagram... Is this presentation prospective?